| mRNA |
Vandetanib |
CCLE |
pan-cancer |
AAC |
0.1 |
0.04 |
| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.071 |
0.05 |
| mRNA |
BRD-K48334597 |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.05 |
| mRNA |
GSK-1904529A |
GDSC1000 |
pan-cancer |
AAC |
0.074 |
0.05 |
| mRNA |
THZ-2-49 |
GDSC1000 |
pan-cancer |
AAC |
0.064 |
0.05 |
| mRNA |
Dasatinib |
FIMM |
pan-cancer |
AAC |
-0.33 |
0.05 |
| mRNA |
XMD13-2 |
GDSC1000 |
pan-cancer |
AAC |
0.067 |
0.05 |
| mRNA |
JW-480 |
CTRPv2 |
pan-cancer |
AAC |
0.076 |
0.06 |
| mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.065 |
0.06 |
| mRNA |
RAF265 |
CCLE |
pan-cancer |
AAC |
-0.1 |
0.06 |